Galectin Therapeutics
GALT
79 hedge funds and large institutions have $26.8M invested in Galectin Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
24% more capital invested
Capital invested by funds: $21.6M → $26.8M (+$5.17M)
17% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 18
8% more funds holding
Funds holding: 73 → 79 (+6)
0.34% more ownership
Funds ownership: 15.32% → 15.65% (+0.34%)
29% less call options, than puts
Call options by funds: $3.89M | Put options by funds: $5.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIA
Soltis Investment Advisors
St. George,
Utah
|
+$346K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$264K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$138K |
| 4 |
BlackRock
New York
|
+$106K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$297K |
| 2 |
Squarepoint
New York
|
-$139K |
| 3 |
Man Group
London,
United Kingdom
|
-$130K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$100K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$80.8K |
GALT Hedge Fund Activity: Q3 2024 in Review
79 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2024, worth a combined $26.8M — up 24% from $21.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GALT positions and 4 closed out — a net gain of 9 holders — while 21 added to existing stakes and 18 trimmed.
The largest buyer was Soltis Investment Advisors, opening a new position worth an estimated $346K. The largest seller was Susquehanna International Group, cutting an estimated $297K.
- 79 institutional investors held Galectin Therapeutics (GALT) as of Q3 2024, up from 73 in Q2 2024.
- Funds reported $26.8M of Galectin Therapeutics stock for Q3 2024, up 24% quarter-over-quarter.
- 13 funds opened new Galectin Therapeutics positions in Q3 2024 and 4 closed out, a net change of +9 holders.
- The largest Galectin Therapeutics buyer in Q3 2024 was Soltis Investment Advisors, an estimated $346K added.
- The largest Galectin Therapeutics seller in Q3 2024 was Susquehanna International Group, an estimated $297K sold.
Based on aggregated 13F filings for Q3 2024.